(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the appointment of Eric Furfine, Ph.D., as president of research and development. Dr. Furfine replaces Burt Adelman, M.D., who has served as the company’s interim president of research and development since its founding. Dr. Adelman will continue to serve as a scientific advisor to the company.
